Colgate-Palmolive Company Form 4 Filings

Colgate-Palmolive director John T. Cahill reported an option exercise-and-sale on August 6, 2026. He exercised stock options for 4,170 shares of common stock at an exercise price of $71.56 per share and sold 4,170 shares at a weighted average price of $93.3712–$93.39, with part of the proceeds delivered to Colgate-Palmolive to pay the option exercise price. After these transactions, he continues to hold 36,357 shares indirectly through a trust.

Colgate-Palmolive Chairman, President & CEO Noel R. Wallace exercised stock options covering 322,042 shares of common stock at an exercise price of $72.2900 per share on August 4–5, 2026, then sold an equal number of shares at weighted average prices of $91.9179 and $92.5215, with a portion of the sale proceeds delivered to the issuer to pay the option exercise price and related tax withholding.

Reported indirect holdings include 54,868 shares held by the issuer's 401(k) plan trustee, 52,000 shares held by a spouse trust, and 335 shares held by another trust.

Colgate-Palmolive director Lorrie M. Norrington acquired 293 shares of common stock at $89.45 per share as a grant under her compensation program. The footnote explains this represents a portion of her annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors. Following this award, she directly holds 42,769 shares of Colgate-Palmolive common stock, indicating this is a small, routine, compensation-related transaction rather than an open-market purchase.

COLGATE PALMOLIVE CO director Brian Newman reported a routine compensation-related equity grant. He acquired 209 shares of common stock at $89.45 per share as a grant or award, representing a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.

Following this grant, Newman directly holds 7,831 shares of Colgate-Palmolive common stock. He is also shown with indirect ownership of 36 shares held by a family trust. These entries reflect compensation and holding disclosures rather than open-market buying or selling.

Colgate-Palmolive director John P. Bilbrey reported a compensation-related share award. He acquired 265 shares of Common Stock at $89.45 per share as a grant or award, increasing his direct holdings to 40,229 shares. A separate entry reflects 4,719 shares held indirectly by a trust. The footnote explains that a portion of his annual cash retainer was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, indicating this was part of routine director compensation rather than an open-market purchase.

Colgate-Palmolive COO, Americas Shane Grant reported a tax-related share disposition tied to equity compensation. On this Form 4, 23,347 shares of Common Stock were withheld at $90.66 per share to cover tax obligations from the vesting of restricted stock units under the company’s incentive compensation plan.

These shares were not sold in the open market but withheld by the issuer for tax payment. After this withholding, Grant directly holds 72,481 shares of Colgate-Palmolive common stock, indicating he retains a substantial equity position following the RSU vesting event.

COLGATE PALMOLIVE CO executive Malcolm Gregory reported an open-market sale of 2,300 shares of Common Stock at $88.44 per share. The sale was a direct transaction and left him with 13,598 shares held directly. He also has 8,599 shares held indirectly through the issuer's 401(k) Plan trustee.

COLGATE PALMOLIVE CO director Brian Newman reported routine equity awards. He received an annual director stock grant of 2,075 shares of common stock, bringing his direct holdings to 7,621 shares. These shares were granted under the company’s incentive compensation plan.

Newman was also granted stock options for 2,424 shares at an exercise price of $86.7400 per share, expiring on May 11, 2034. The options become exercisable in equal annual installments over three years starting on the first anniversary of the May 11, 2026 grant date. In addition, 36 shares are held indirectly through a family trust.

COLGATE PALMOLIVE CO director Kimberly A. Nelson received new equity compensation awards. On May 11, 2026, she acquired 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing her direct holdings to 11,634 shares.

On the same date, she also received a stock option for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. This option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the grant date. The filing also lists additional indirect holdings through a trust, spouse, and a family trust.

Colgate-Palmolive director Martina Hundmejean received equity awards as part of her annual compensation. She was granted 2,075 shares of Common Stock at no cost, credited to a stock unit account under the company’s incentive compensation plan, bringing her direct holdings to 16,206 shares.

She also received a stock option for 2,424 shares of Common Stock with an exercise price of $86.74 per share. The option vests in equal annual installments over three years, starting on the first anniversary of the May 11, 2026 grant date. These are compensation-related grants, not open-market purchases or sales.

Colgate-Palmolive director Harris C. Martin received new equity awards. On May 11, 2026, he was granted 1,556 shares of Common Stock as an annual director stock grant under the company’s incentive compensation plan.

He was also granted stock options for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. These options become exercisable in equal annual installments over three years beginning on the first anniversary of the grant date. Following the stock grant, he directly holds 24,517 common shares, plus the newly granted options.

Colgate-Palmolive director Lorrie M. Norrington reported compensation-related equity awards. She received an annual director stock grant of 2,075 shares of common stock credited to a stock unit account under the company’s incentive compensation plan, bringing her direct common stock holdings to 42,312 shares.

She was also granted a stock option covering 2,424 shares of common stock at an exercise price of $86.74 per share. This option expires on May 11, 2034 and becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date.

Colgate-Palmolive director Lisa Edwards received routine equity awards as part of her compensation. She was granted 2,075 shares of common stock and 2,424 stock options on May 11, 2026 under the company’s incentive compensation plan. After the grant, she directly owns 18,182 common shares.

The options allow her to buy 2,424 common shares at an exercise price of $86.74 per share and expire on May 11, 2034. They become exercisable in equal annual installments over three years, starting on the first anniversary of the grant date.

COLGATE PALMOLIVE CO director John T. Cahill reported routine equity compensation awards. On May 11, 2026, he received an annual director stock grant of 2,075 shares of common stock, increasing his directly held shares to 28,216.

He also received an annual director stock option grant for 2,424 shares of common stock at a conversion price of $86.74 per share, with options vesting in equal annual installments over three years beginning on the first anniversary of the grant date and expiring on May 11, 2034. Separately, 36,357 shares are reported as held indirectly through a trust, which includes 2,019 shares previously reported as directly owned.

Colgate-Palmolive director Christopher S. Boerner reported equity compensation awards. He received an annual director stock grant of 1,383 shares of common stock under the company’s incentive compensation plan, leaving him with 1,383 common shares directly owned after the award.

He was also granted a stock option for 2,020 shares of common stock with an exercise price of $86.74 per share, expiring on May 11, 2034. The option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date. These are compensation-related awards rather than open-market purchases or sales.

COLGATE PALMOLIVE CO director John P. Bilbrey reported routine equity compensation and updated holdings. He received a grant of 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing his direct holdings to 39,820 shares. He also received an annual director stock option grant for 2,424 shares at an exercise price of $86.74 per share, expiring on May 11, 2034, which becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date. In addition, a separate entry reflects 4,719 shares of Common Stock held indirectly by a trust.

Colgate-Palmolive Chief People Officer Sally Massey sold 8,599 shares of Common Stock in an open-market transaction. The sale took place on May 7, 2026 at a weighted average price of $87.4093 per share, with individual prices ranging from $87.36 to $87.53.

After the sale, Massey directly owned 13,785 shares of Colgate-Palmolive common stock and indirectly held 8,152 shares through the issuer’s 401(k) plan trustee.

NORRINGTON LORRIE M reported acquisition or exercise transactions in this Form 4 filing.

COLGATE PALMOLIVE CO director Lorrie M. Norrington received an equity award of 294 shares of Common Stock, valued at $89.05 per share. The award represents a portion of her annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, and increases her direct holdings to 40,160 shares.

Newman Brian reported acquisition or exercise transactions in this Form 4 filing.

Colgate-Palmolive director Brian Newman received 210 shares of Common Stock as a grant on April 1, 2026, at $89.05 per share. The award represents a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.

After this grant, he directly holds 5,534 shares of Colgate-Palmolive Common Stock. In addition, 36 shares are held indirectly through a family trust. This filing reflects routine director compensation rather than an open-market purchase or sale.

Colgate-Palmolive director John P. Bilbrey acquired 266 shares of Common Stock as a compensation award. The shares, valued at $89.05 each, represent a portion of his annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.

After this grant, he directly holds 37,665 Colgate-Palmolive shares and has an additional 4,719 shares held indirectly by a trust. The transaction reflects routine director compensation rather than an open-market purchase.

Colgate-Palmolive Chief Growth Officer John Hazlin reported equity compensation activity involving company common stock. On February 23, 2026, he acquired 12,803 shares through the vesting of performance-based restricted stock units granted under the incentive compensation plan. On the same date, 6,117 shares were disposed of at $97.10 per share to cover tax withholding related to that vesting. After these transactions, Hazlin directly owned 24,422 shares and indirectly held 5,452 shares through the issuer’s 401(k) plan trustee.

Colgate-Palmolive’s Chief Legal Officer and Secretary Jennifer Daniels reported equity compensation activity in Common Stock. She acquired 25,742 shares through the vesting of previously granted performance-based restricted stock units that were earned under the company’s incentive compensation plan and settled in stock. To cover tax liabilities from this vesting, 12,351 shares were withheld at a price of $97.10 per share. After these transactions, she directly held 89,844 shares and indirectly held 1,837 shares through the issuer’s 401(k) plan trustee.

Colgate-Palmolive EVP and Controller Malcolm Gregory reported equity award activity in company stock. He acquired 6,268 shares of Common Stock at a price of $0.0000 per share through the vesting of previously granted performance-based restricted stock units under the issuer's incentive compensation plan, which are settled solely in shares.

On the same date, 2,260 shares of Common Stock were disposed of at $97.1000 per share to cover tax liabilities associated with the PBRSU vesting. Following these transactions, he directly held 15,898 shares of Common Stock. In addition, 8,554 shares are held indirectly through the issuer's 401(k) plan trustee.

Colgate-Palmolive Chief Human Resources Officer Sally Massey reported stock-based compensation activity tied to performance awards. She acquired 16,805 shares of Common Stock at no cost from the vesting of previously granted performance-based restricted stock units earned under the company’s incentive plan. To cover tax obligations from this vesting, 8,206 shares were disposed of through a tax-withholding transaction at $97.10 per share, rather than an open-market sale. After these transactions, she directly owns 22,384 shares of Common Stock and indirectly holds 8,111 shares through the issuer’s 401(k) plan trustee.

Colgate-Palmolive Chief Financial Officer Stanley J. Sutula III reported equity compensation activity involving the company’s common stock. He acquired 38,678 shares on February 23, 2026 through the vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan.

On the same date, 19,746 shares were disposed of to cover tax withholding related to this vesting, rather than through an open-market sale. After these transactions, he held 74,320 shares directly and 328 shares indirectly through the issuer’s 401(k) plan trustee.

Colgate-Palmolive COO Panagiotis Tsourapas received 25,742 shares of Common Stock on February 23, 2026 from vesting of performance-based restricted stock units earned under the company’s incentive plan. No cash changed hands for this award.

On the same date, 13,081 shares were withheld at $97.10 per share to cover related tax liabilities. After these transactions, he directly holds 21,629 shares, plus 4,568 shares through the issuer’s 401(k) plan trustee and 62,240 shares held by a trust.

Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported equity award activity in company stock. On February 23, 2026, he acquired 136,710 shares of Common Stock at $0.00 per share through vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan. On the same date, 68,252 shares at $97.10 per share were withheld to cover tax obligations related to this vesting, a non-open-market disposition. Following these transactions, he directly owned 361,921 shares of Common Stock. He also had indirect holdings of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares via a spouse trust, and 335 shares via another trust.

Tsourapas Panagiotis reported multiple insider transaction types in a Form 4 filing for CL. The filing lists transactions totaling 150,000 shares at a weighted average price of $85.99 per share. Following the reported transactions, holdings were 19,938 shares.

Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share. A portion of the sale proceeds was delivered to the company to pay the option exercise price and related tax withholding. After these transactions, John directly owned 17,645 shares and indirectly held 5,452 shares through the issuer's 401(k) plan trustee.

Colgate-Palmolive executive Malcolm Gregory reported an employee stock option exercise and related share sale. On February 6, 2026, he exercised options for 12,747 shares of common stock at $76.41 per share under the company’s incentive compensation plan.

That same day, he sold 12,747 shares of Colgate-Palmolive common stock in market transactions at a weighted average price of $94.9103 per share, with individual trades ranging from $94.79 to $95.01. After these transactions, he directly owned 11,879 shares and held an additional 8,554 shares indirectly through the issuer’s 401(k) plan trustee.

Colgate-Palmolive Chief Human Resources Officer Sally Massey reported an option exercise and related share sale. On February 5, 2026, she exercised stock options for 15,851 shares of common stock at $76.41 per share, awarded under the company’s incentive compensation plan.

That same day, she sold 15,851 shares of common stock at a weighted average price of $95.0279, with part of the proceeds used to pay the option exercise price and related tax withholding. After these transactions, she directly owned 13,751 shares of Colgate-Palmolive common stock and held an additional 8,111 shares indirectly through the issuer’s 401(k) plan trustee.

Colgate-Palmolive’s Chief Financial Officer, Stanley J. Sutula III, exercised stock options and sold shares in a planned transaction. On February 4, 2026, he exercised 97,843 stock options at an exercise price of $81.78 per share under the company’s incentive compensation plan.

That same day, he sold 97,843 shares of common stock at a weighted average price of $94.2662 per share, with a portion of the proceeds delivered to Colgate-Palmolive to cover the option exercise price and related tax withholding. After these transactions, he directly owned 55,310 common shares and indirectly held 328 shares through the issuer’s 401(k) plan trustee.

Colgate-Palmolive’s Chief Legal Officer and Secretary, Jennifer Daniels, reported an option exercise and share sale. On February 4, 2026, she exercised stock options for 22,000 shares of common stock at $72.29 per share under the company’s incentive plan, increasing her direct holdings to 98,406 shares.

That same day, she sold 22,000 shares of common stock at a weighted average price of $94.3363 per share in multiple transactions, leaving 76,406 shares held directly. A footnote explains that part of the sale proceeds went to Colgate-Palmolive to cover the option exercise price and related tax withholding. She also holds 1,837 shares indirectly through the issuer’s 401(k) plan trustee.

Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported a sale of common stock. On February 4, 2026, he sold 45,568 shares of Colgate-Palmolive common stock at a weighted average price of $93.9145 per share, in multiple transactions within a stated price range.

After this sale, Wallace directly owned 293,188 common shares. He also reported indirect ownership of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.

Colgate-Palmolive Company director reports stock acquisition under compensation plan

A director of Colgate-Palmolive Company reported acquiring 238 shares of common stock on 01/02/2026 at a price of $78.66 per share. The filing notes this represents a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors.

Following this transaction, the director beneficially owns 5,313 shares of Colgate-Palmolive common stock directly and 36 shares indirectly through a family trust.

Colgate-Palmolive Company director reports a small equity transaction. A board member acquired 333 shares of Colgate-Palmolive common stock on 01/02/2026 at a price of $78.66 per share, according to a Form 4 filing. After this transaction, the director beneficially owns 39,648 shares held directly.

The filing explains that the transaction reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The form is signed by an attorney-in-fact on 01/06/2026, indicating the report was made on the director’s behalf.

Colgate-Palmolive Company director reports deferred stock award

A director of Colgate-Palmolive Company reported acquiring 301 shares of common stock on 01/02/2026 at a price of $78.66 per share. According to the footnote, this reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, rather than a market purchase for cash.

Following this transaction, the director beneficially owns 37,195 shares directly and 4,719 shares indirectly through a trust. The filing confirms the individual’s status as a director and that the report is filed for one reporting person.

Colgate-Palmolive Company Chairman, President & CEO and director reported a routine tax-related share withholding. On 12/03/2025, the executive disposed of 1,307 shares of common stock at $78.2 per share, coded as an "F" transaction, meaning shares were withheld to cover Medicare and income tax owed on previously granted restricted stock units. The executive continues to hold those restricted stock units, reduced only by the shares used for required tax withholding.

After this transaction, the executive beneficially owns 338,756 shares directly. Additional indirect holdings include 53,923 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.

Colgate-Palmolive Company officer reports small share withholding for taxes. A company officer serving as COO, Eur., APac, Afr Eur, Skin reported a Form 4 transaction involving Colgate-Palmolive common stock. On 12/03/2025, 221 shares of common stock were disposed of at $78.2 per share, coded as transaction type F, which represents shares withheld to cover Medicare and income tax on previously granted restricted stock units under the company’s incentive compensation plan.

After this tax withholding, the officer beneficially owns 10,415 shares directly, 4,538 shares indirectly through the issuer's 401(k) plan trustee, and 60,745 shares indirectly through a trust. The filing notes that the officer continues to hold the original restricted stock units granted, reduced only by the amount required for this tax withholding.

Colgate-Palmolive Company’s Chief Financial Officer, reported on a Form 4 that shares of company stock were withheld to cover taxes on previously granted restricted stock units. On 12/03/2025, 385 shares of common stock were disposed of at a price of $78.2 per share through tax withholding, coded as transaction type "F," which indicates payment of tax liability from equity awards.

After this transaction, the officer beneficially owns 55,310 shares of Colgate-Palmolive common stock directly, and an additional 326 shares indirectly through the issuer’s 401(k) plan trustee. The filing clarifies that the underlying restricted stock units remain held by the officer, reduced only by the amount required for Medicare and income tax withholding.

Colgate-Palmolive Company executive Kristine Hutchinson, EVP and Controller, reported a small tax-related stock transaction. On 12/03/2025, 41 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share under transaction code "F," which indicates shares were withheld to cover taxes on previously granted restricted stock units.

After this transaction, Hutchinson beneficially owns 11,879 shares of Colgate-Palmolive common stock directly and 8,497 shares indirectly through the issuer's 401(k) plan trustee. The explanation notes that she continues to hold the original restricted stock units, reduced only by the number of shares withheld to satisfy Medicare and income tax obligations.

Colgate-Palmolive Company’s Chief Growth Officer reported a small share transaction involving company stock. On 12/03/2025, 156 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share in a transaction coded “F,” which indicates shares were withheld by the company to cover Medicare and income tax obligations tied to previously granted restricted stock units. After this tax withholding, the officer beneficially owns 17,645 shares directly and 5,416 shares indirectly through the issuer’s 401(k) plan trustee. The underlying restricted stock units remain in place, reduced only by the shares used for required tax withholding.

Colgate-Palmolive (CL) reported a routine insider tax-withholding transaction by its Chief Legal Officer and Secretary. On 12/03/2025, the executive had 213 shares of common stock withheld at a price of $78.2 per share, coded as an "F" transaction, which indicates shares were withheld to cover Medicare and income tax obligations on previously granted restricted stock units under the company’s incentive compensation plan.

After this non-open-market transaction, the executive beneficially owns 76,406 shares of Colgate-Palmolive common stock directly and an additional 1,825 shares indirectly through the issuer's 401(k) plan trustee. The filing notes that the restricted stock units themselves continue to be held, reduced only by the amount of shares withheld for taxes.

Colgate-Palmolive Company (CL) reported an insider stock transaction by its Chief Human Resources Officer. On 11/21/2025, the officer sold 1,237 shares of Colgate-Palmolive common stock at a price of $80.89 per share. After this sale, the officer beneficially owned 13,751 shares directly and 8,058 shares indirectly through the issuer's 401(k) plan trustee. The filing was made on a Form 4, which discloses changes in insider ownership.

Brian Newman, a director of Colgate-Palmolive Co. (CL), reported a non-derivative acquisition of 228 shares of common stock on 10/01/2025 at a price of $82.13 per share. Following the transaction he directly beneficially owns 5,065 shares and indirectly holds 36 shares through a family trust. The filing identifies the purchase code A(1), and the explanation states this represents a portion of the annual cash retainer deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Lorrie M. Norrington, a director of Colgate-Palmolive Company (CL), reported a transaction dated 10/01/2025 in which she acquired 319 shares of Colgate common stock at a price of $82.13 per share. After this transaction she beneficially owned 39,061 shares in a direct ownership form. The filing states the purchase reflects a portion of an annual cash retainer deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

John P. Bilbrey, a director of Colgate-Palmolive Company (CL), reported an acquisition on 10/01/2025 of 289 shares of the issuer's common stock at a price of $82.13 per share. Following the transaction, Mr. Bilbrey directly beneficially owns 36,658 shares and indirectly owns 4,719 shares through a trust. The filing states the reason for the acquisition: a portion of his annual cash retainer was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors, resulting in the issuance of common stock.

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025. No derivative transactions, dispositions, or other changes are disclosed in this Form 4.